Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms: A Randomized, Double-blind, Placebo-controlled Trial

NCT06154408 is registered in ClinicalTrials.gov with S.LAB (SOLOWAYS) as lead sponsor.

NCT NCT06154408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06154408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms: A Randomized, Double-blind, Placebo-controlled Trial
Lead sponsor
S.LAB (SOLOWAYS)
Phase
Not applicable
Overall status
Completed
Start date
February 10, 2022
Completion date
November 1, 2022
Enrollment
102 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ldl hyperlipoproteinemia, low-density-lipoprotein-type [ldl] hyperlipoproteinemia, triglyceride storage type i or ii disease